Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| DGX | QUEST DIAGNOSTICS INC | 2026-04-02 16:42:56 | 198.02 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DGX | 0001022079 | QUEST DIAGNOSTICS INC | US74834L1008 | 8MCWUBXQ0WE04KMXBX50 | 161387862 | NYSE | 8071 | Services-Medical Laboratories | 1231 | DE | 500 PLAZA DRIVE | SECAUCUS | NJ | 07094 | UNITED STATES | US | 9735202700 | 500 PLAZA DRIVE, SECAUCUS, NJ, 07094 | 500 PLAZA DRIVE, SECAUCUS, NJ, 07094 | CORNING CLINICAL LABORATORIES INC | Health care | 1967 | Jim Davis | 56,000 | https://questdiagnostics.com | 20,000,000,000 | 162,000,000 | 109,866,320 | Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe. | 2026-04-02 15:39:09 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 20,000,000,000 | 4,800,000,000 | 31.5789 | 109,866,320 | -1,111,749 | -1.0018 |
| 2024 | 15,200,000,000 | -500,000,000 | -3.1847 | 110,978,069 | 270,776 | 0.2446 |
| 2023 | 15,700,000,000 | 300,000,000 | 1.9481 | 110,707,293 | -615,710 | -0.5531 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Catherine T. Doherty | Executive Vice President | 2024 | 618,269 | 0 | 1,593,772 | 477,798 | 46,420 | 3,286,080 |
| Michael E. Prevoznik | General Counsel, Senior Vice President | 2024 | 550,000 | 0 | 1,086,688 | 371,910 | 45,174 | 2,428,646 |
| James E. Davis | President, Chairman, Chief Executive Officer | 2024 | 1,250,000 | 0 | 8,239,724 | 1,811,250 | 260,258 | 14,404,862 |
| Sam A. Samad | Chief Financial Officer, Executive Vice President | 2024 | 668,269 | 0 | 2,028,350 | 580,993 | 90,971 | 4,068,464 |
| Karthik Kuppusamy | Senior Vice President | 2024 | 543,269 | 0 | 978,040 | 367,359 | 51,664 | 2,277,691 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 57,000 |
| 2024 | 56,000 |
| 2023 | 48,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 11,035,000,000 | 9,872,000,000 | 9,252,000,000 |
| Cost Of Revenue | 7,370,000,000 | 6,628,000,000 | 6,199,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | — | — | — |
| General And Administrative Expenses | 1,967,000,000 | 1,770,000,000 | 1,642,000,000 |
| Operating Expenses | 9,479,000,000 | 8,526,000,000 | 7,990,000,000 |
| Operating Income | 1,556,000,000 | 1,346,000,000 | 1,262,000,000 |
| Net Income | 992,000,000 | 871,000,000 | 854,000,000 |
| Earnings Per Share Basic | 8.87 | 7.78 | 7.59 |
| Earnings Per Share Diluted | 8.75 | 7.69 | 7.49 |
| Weighted Average Shares Outstanding Basic | 111,000,000 | 111,000,000 | 112,000,000 |
| Weighted Average Shares Outstanding Diluted | 113,000,000 | 113,000,000 | 113,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 420,000,000 | 549,000,000 | 686,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 1,408,000,000 | 1,304,000,000 | 1,210,000,000 |
| Inventories | 189,000,000 | 188,000,000 | 190,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | 43,000,000 | 40,000,000 | 36,000,000 |
| Total Assets Current | 2,378,000,000 | 2,392,000,000 | 2,372,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 2,203,000,000 | 2,113,000,000 | 1,816,000,000 |
| Other Assets Non Current | 270,000,000 | 255,000,000 | 198,000,000 |
| Total Assets Non Current | 13,847,000,000 | 13,761,000,000 | 11,650,000,000 |
| Total Assets | 16,225,000,000 | 16,153,000,000 | 14,022,000,000 |
| Accounts Payable | 307,000,000 | 287,000,000 | 378,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 504,000,000 | 602,000,000 | 303,000,000 |
| Other Liabilities Current | 338,000,000 | 306,000,000 | 287,000,000 |
| Total Liabilities Current | 2,278,000,000 | 2,169,000,000 | 1,815,000,000 |
| Long Term Debt | 5,671,000,000 | 6,217,000,000 | 4,713,000,000 |
| Other Liabilities Non Current | 957,000,000 | 938,000,000 | 876,000,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 2,000,000 | 2,000,000 | 2,000,000 |
| Retained Earnings | 9,994,000,000 | 9,360,000,000 | 8,825,000,000 |
| Accumulated Other Comprehensive Income | -27,000,000 | -88,000,000 | -14,000,000 |
| Total Shareholders Equity | 7,170,000,000 | 6,778,000,000 | 6,307,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 570,000,000 | 493,000,000 | 439,000,000 |
| Share Based Compensation Expense | 88,000,000 | 88,000,000 | 77,000,000 |
| Other Non Cash Income Expense | -24,000,000 | -15,000,000 | -41,000,000 |
| Change In Accounts Receivable | 106,000,000 | 71,000,000 | 15,000,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 129,000,000 | -67,000,000 | -55,000,000 |
| Change In Other Liabilities | -3,000,000 | 79,000,000 | 73,000,000 |
| Cash From Operating Activities | 1,886,000,000 | 1,334,000,000 | 1,272,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 527,000,000 | 425,000,000 | 408,000,000 |
| Acquisition Of Business | 101,000,000 | 2,164,000,000 | 611,000,000 |
| Other Investing Activities | 3,000,000 | -41,000,000 | 42,000,000 |
| Cash From Investing Activities | -631,000,000 | -2,548,000,000 | -1,061,000,000 |
| Tax Withholding For Share Based Compensation | 45,000,000 | 24,000,000 | 28,000,000 |
| Payments Of Dividends | 358,000,000 | 336,000,000 | 319,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 450,000,000 | 151,000,000 | 275,000,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 39,000,000 | 21,000,000 | 14,000,000 |
| Cash From Financing Activities | -1,388,000,000 | 1,084,000,000 | 160,000,000 |
| Change In Cash | -129,000,000 | -137,000,000 | 371,000,000 |
| Cash At End Of Period | 420,000,000 | 549,000,000 | 686,000,000 |
| Income Taxes Paid | 169,000,000 | 256,000,000 | 317,000,000 |
| Interest Paid | 280,000,000 | 262,000,000 | 134,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 8.87 | 7.78 | 7.59 |
| Price To Earnings Ratio | 19.5637 | 19.3907 | 18.166 |
| Earnings Growth Rate | 14.0103 | 2.5033 | -6.2963 |
| Price Earnings To Growth Ratio | 1.3964 | 7.7461 | -2.8852 |
| Book Value Per Share | 125.6486 | 125.982 | 108.9911 |
| Price To Book Ratio | 1.3811 | 1.1975 | 1.2651 |
| Ebitda | 1,467,000,000 | 1,419,000,000 | 1,773,000,000 |
| Enterprise Value | 25,016,830,000 | 23,015,460,000 | 19,772,560,000 |
| Dividend Yield | 0.0186 | 0.0201 | 0.0207 |
| Dividend Payout Ratio | 0.3609 | 0.3858 | 0.3735 |
| Debt To Equity Ratio | 0.8612 | 1.006 | 0.7953 |
| Capital Expenditures | 660,000,000 | 790,000,000 | 489,000,000 |
| Free Cash Flow | 1,226,000,000 | 544,000,000 | 783,000,000 |
| Return On Equity | 0.1384 | 0.1285 | 0.1354 |
| One Year Beta | 0.2418 | 0.2492 | 0.3796 |
| Three Year Beta | 0.2737 | 0.4613 | 0.446 |
| Five Year Beta | 0.371 | 0.5898 | 0.6223 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| WENTWORTH TIMOTHY C | Director | 2026-04-01 | 198 | A | 198 |
| Plewman Patrick | SVP for Diagnostic Services | 2026-03-05 | 2,855 | D | 15,198 |
| PREVOZNIK MICHAEL E | SVP & General Counsel | 2026-03-05 | 3,878 | D | 37,557 |
| Doherty Catherine T. | EVP, Regional Businesses | 2026-03-05 | 5,558 | D | 67,122 |
| KUPPUSAMY KARTHIK | SVP, Clinical Solutions | 2026-03-04 | 6,200 | A | 16,069 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Thomas H Tuberville | Senator | 2024-02-14 | Sale (Partial) | 2024-01-03 | Joint | $15,001 - $50,000 |
| Thomas R Carper | Senator | 2024-01-03 | Sale (Partial) | 2023-12-11 | Spouse | $1,001 - $15,000 |
| Thomas H Tuberville | Senator | 2021-07-23 | Purchase | 2021-03-29 | Joint | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2021-05-17 | Purchase | 2020-04-02 | Spouse | $1,001 - $15,000 |
| Thomas R Carper | Senator | 2020-05-04 | Purchase | 2020-04-02 | Spouse | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Julia Letlow | 2026-01-13 | LA05 | Sale | 2025-07-24 | — | $1,001 - $15,000 |
| Julia Letlow | 2026-01-13 | LA05 | Purchase | 2025-04-28 | — | $1,001 - $15,000 |
| Julie Johnson | 2025-12-11 | TX32 | Sale | 2025-11-03 | Joint | $1,001 - $15,000 |
| Carol Devine Miller | 2025-04-11 | WV01 | Sale | 2025-03-10 | — | $1,001 - $15,000 |
| Earl Blumenauer | 2024-05-04 | OR03 | Sale | 2024-04-04 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| First County Bank /CT/ | 2026-03-31 | 217,537 | 1,110 | 195.9793 |
| ADIRONDACK TRUST CO | 2026-03-31 | 3,135 | 16 | 195.9375 |
| Coastline Trust Co | 2026-03-31 | 74,276 | 379 | 195.9789 |
| Ares Financial Consulting, LLC | 2026-03-31 | 7,512 | 38 | 197.6842 |
| Somerset Trust Co | 2026-03-31 | 1,810,463 | 9,238 | 195.98 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| VANGUARD INTERNATIONAL EQUITY INDEX FUNDS | 2026-01-31 | Admiral Shares | VTWAX | 84,717 | 15,844,620.51 | 0.0197 |
| VANGUARD INTERNATIONAL EQUITY INDEX FUNDS | 2026-01-31 | Institutional Shares | VTWIX | 84,717 | 15,844,620.51 | 0.0197 |
| VANGUARD INTERNATIONAL EQUITY INDEX FUNDS | 2026-01-31 | ETF Shares | VT | 84,717 | 15,844,620.51 | 0.0197 |
| VANGUARD SPECIALIZED FUNDS | 2026-01-31 | Admiral Shares | VDADX | 615,328 | 115,084,795.84 | 0.0947 |
| VANGUARD SPECIALIZED FUNDS | 2026-01-31 | ETF Shares | VIG | 615,328 | 115,084,795.84 | 0.0947 |